Evidence map›Paper›PMID 34161676›Full record

ArticleCancer reports (Hoboken, N.J.)2021

Role of molecular signature to differentiate second primary lung cancer from metastasis in a patient with squamous cell carcinoma of oral cavity.

Emrullah Yilmaz, Gregory N Gan, Thomas M Schroeder, Andrew Cowan, Nancy Joste

Open access · goldAbstract readCase Reports
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Emrullah YilmazDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0003-2308-713X
Gregory N GanDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Thomas M SchroederUniversity of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
Andrew CowanUniversity of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
Nancy JosteDepartment of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
University of New Mexico · USCleveland Clinic · USUniversity of Kansas Medical Center · US

Funding

Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANDREW K. GODWIN · 2019 to 2026
$21.5M
NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

backgroundLung is the most common site of distant metastasis for patients with head and neck squamous cell carcinoma (HNSCC). However, differentiating second primary lung cancers from metastasis may be difficult for p16 negative HNSCC. CASE: We describe a case of oral cavity squamous cell carcinoma (SCC) who was found to have lung nodule and hilar lymphadenopathy (LAD) after surgery and radiation therapy. Hilar node was consistent with SCC however, it was difficult to differentiate second primary lung cancer and metastasis from oral cavity SCC. Next-generation sequencing was done for the primary oral cavity and the hilar node. Both samples had the same type of TP53 mutation and variants of unknown significance suggesting metastatic HNSCC. He was treated with a chemotherapy regimen for metastatic HNSCC.

conclusionMolecular studies can help to differentiate metastasis from second primary lung cancers for p16 negative HNSCC.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDiagnosis, DifferentialHumansLungLung NeoplasmsMaleMouthMouth NeoplasmsMutationNeoplasms, Second PrimarySquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53head and neck cancerlung cancerlung metastasismolecular signature

Identifiers

PMID34161676
PMCPMC8388157
OpenAlexW3173501253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.